In a report released yesterday, Vamil Divan from Mizuho Securities upgraded Eli Lilly & Co (LLY) to Buy, with a price target of $222.00. The company’s shares closed last Monday at $212.35.
According to TipRanks.com, Divan is a 1-star analyst with an average return of -0.8% and a 48.3% success rate. Divan covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Satsuma Pharmaceuticals, and ACADIA Pharmaceuticals.
Currently, the analyst consensus on Eli Lilly & Co is a Moderate Buy with an average price target of $194.90, a -6.4% downside from current levels. In a report issued on January 11, J.P. Morgan also maintained a Buy rating on the stock.
See today’s analyst top recommended stocks >>
Eli Lilly & Co’s market cap is currently $197.2B and has a P/E ratio of 33.60. The company has a Price to Book ratio of -30.39.
Based on the recent corporate insider activity of 75 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of LLY in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Eli Lilly & Co. engages in the discovery, development, manufacture and sale of pharmaceutical products. Its products include Forteo, Adrica, BAQSIMI, Basaglar and Glucagn. The company was founded by Eli Lilly on May 1876 and is headquartered in Indianapolis, IN.
